Quantcast
Better Marijuana Stock: Cronos Group vs. The Green Organic Dutchman | The Mesh Report

Better Marijuana Stock: Cronos Group vs. The Green Organic Dutchman

Growth Stock Network April 11, 2019 Comments Off on Better Marijuana Stock: Cronos Group vs. The Green Organic Dutchman

Cronos Group (NASDAQ:CRON) has received plenty of attention from U.S. investors in recent months. The Green Organic Dutchman (NASDAQOTH:TGODF) for the most part hasn’t benefited from a lot of publicity in America. But guess which stock has performed better so far this year? Pat yourself on the back if you answered The Green Organic Dutchman (TGOD).

However, Cronos Group has a much better long-term track record, even ranking as the top-performing marijuana stock of all time. Past performance doesn’t matter much in determining which of these two Canadian marijuana stocks is the better pick now, though. Here’s how Cronos and TGOD stack up against each other on what does matter.

The case for Cronos Group

There are at least 1.8 billion reasons to like Cronos Group. Those reasons correspond to the dollars invested in Cronos by tobacco giant Altria (NYSE:MO) in exchange for a 45% stake in the company. Cronos benefits from its relationship with Altria in two important ways.

First, the company now has a nice cash stockpile. Cronos plans to put that money to good use by expanding its product development and commercialization capabilities. Altria’s cash should also help Cronos reduce its dependence on dilution-causing stock offerings.

Second, Cronos now has a huge partner at its side with a long history of building successful commercial brands across the world. There are several similarities between the cannabis and tobacco industries that could make Altria’s relationship with Cronos more valuable over time.

Cronos also has another partnership that could be really important in the not-too-distant future. Last year, Cronos teamed up with Gingko Bioworks to produce cannabinoids from engineered yeast strains. The potential for this technology is enormous in that it could slash the time and expenses associated with producing cannabinoids from cannabis plants.

In the meantime, Cronos is making more money than ever thanks mainly to the Canadian adult-use recreational marijuana market. The company also has a good start on the international front, with partnerships and joint ventures in Europe, Australia, Israel, and Colombia.

Continue Reading At Growth Stock Network



Comments are closed.